Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29280909 | 0.98 | EPHX2 (0.39) | EPHX2EPHX1ALDH1A1THRBATM | |
| SCHEMBL4122196 | 0.87 | HRH4 (0.42) | EPHX2EPHX1ALDH1A1THRBATM | |
| SCHEMBL18284105 | 0.87 | HRH4 (0.42) | EPHX2EPHX1ALDH1A1THRBATM | |
| SCHEMBL15703919 | 0.87 | HRH4 (0.42) | EPHX2EPHX1ALDH1A1THRBATM | |
| Hydrochloric Acid SCHEMBL6110472 | 0.85 | HRH4 (0.41) | EPHX2EPHX1ALDH1A1THRBATM | |
| Hydrochloric Acid SCHEMBL21772820 | 0.85 | HRH4 (0.41) | EPHX2EPHX1ALDH1A1THRBATM | |
| SCHEMBL10156619 | 0.84 | ALDH1A1 (0.52) | EPHX2EPHX1ALDH1A1THRBATM | |
| SCHEMBL2888489 | 0.82 | EPHX2 (0.58) | EPHX2EPHX1 | |
| SCHEMBL16835513 | 0.81 | ITGB3 (0.36) | EPHX2ALDH1A1 | |
| SCHEMBL14018620 | 0.80 | POLB (0.62) | EPHX2EPHX1ALDH1A1THRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102171-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | claimed |
| EP-2069327-A1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-06-17 | — | — | EP | claimed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | claimed |
| WO-2008022979-A1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | claimed |
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3814345-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| CN-118119629-A | Nitrogen-containing heterocyclic compound and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4313991-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| WO-2005003127-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF CXCR3 FUNCTION | CELLTECH R & D LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-6803364-B1 | FOR TREATING EOSINOPHIL-DEPENDENT INFLAMMATORY DISEASES SUCH AS ASTHMA | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-12 | — | — | US | disclosed |
| CN-1134431-C | 2,4-diaminopyrimidine derivatives as dopamine D4 receptor antagonists | ��˹��ŵ�� | 2004-01-14 | — | — | CN | disclosed |
| CN-1330643-A | IL-5 inhibiting azauracil pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-09 | — | — | CN | disclosed |
| EP-1140873-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037451-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
| CN-1218466-A | 2,4-diaminopyrimidine derivatives as dopamine d4 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 1999-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | CYP3A7, NISCH, ARG1 | EPHX2 4487/4885EPHX1 4190/4885ALDH1A1 1594/4885 |
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | EPHX2 2582/4885EPHX1 2140/4885ALDH1A1 1911/4885 |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | EPHX2 4265/4885EPHX1 4226/4885ALDH1A1 3608/4885 |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | EPHX2 2516/4885EPHX1 1773/4885ALDH1A1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.